CD1c+ and CD141+ myeloid dendritic cell vaccine

This investigational cell therapy consists of two distinct subsets of primary myeloid dendritic cells (mDCs) isolated directly from a patient's peripheral blood: **CD1c+ (cDC2)** and **CD141+ (cDC1)** cells. Unlike traditional monocyte-derived dendritic cell (moDC) vaccines, which require extensive ex vivo differentiation, these "natural" dendritic cells are isolated in their functional state, potentially offering superior migratory and immunostimulatory capabilities. CD1c+ mDCs are potent stimulators of CD4+ helper T cells and induce Th1/Th17 responses, while CD141+ mDCs are rare but highly specialized for the cross-presentation of antigens to CD8+ cytotoxic T cells. By administering a combination of both subsets loaded with tumor-associated antigens (via peptides or mRNA), the therapy aims to generate a comprehensive and synergistic anti-tumor immune response. Developed primarily by the Radboud University Medical Centre, this approach has been evaluated in clinical trials for melanoma and prostate cancer to overcome the immunosuppressive environment of advanced malignancies.

Other names

CD1c+ myeloid dendritic cells + CD141+ myeloid dendritic cellsNatural myeloid dendritic cell vaccineNatural mDC vaccineAutologous natural myeloid dendritic cell vaccinenDCs